Abiraterone (Abiraterone Acetate)

Generic Name

Abiraterone Acetate

Brand Names

Abiraterone, Zytiga, Akeega, YONSA, Abirtega

FDA approval date: April 28, 2011

Classification: Cytochrome P450 17A1 Inhibitor

Form: Tablet

What is Abiraterone (Abiraterone Acetate)?

Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer Metastatic high-risk castration-sensitive prostate cancer Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer . metastatic high-risk castration-sensitive prostate cancer .

Approved To Treat

Prostate Cancer

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

Enrollment Status: Recruiting

Publish Date: October 14, 2025

Intervention Type: Drug

Study Phase: Phase 3

Summary: Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after ...

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Enrollment Status: Recruiting

Publish Date: October 14, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about: * The safety of the study treatment and if people tolerate it. * A safe dose level of I-DXd that can be used with other treatments. * Partici...

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)

Who is this study for: Patients with Prostate Cancer

Enrollment Status: Recruiting

Publish Date: October 14, 2025

Intervention Type: Drug, Procedure, Radiation, Other

Study Drugs: Goserelin, Histrelin, Leuprolide & Triptorelin, Androgen Deprivation Therapy + Nilutamide, Flutamide, & Bicalutamide, Degarelix, Androgen Deprivation Therapy + Docetaxel +/- Prednisone, Androgen Deprivation Therapy + Abiraterone + Prednisone, Androgen Deprivation Therapy + Abiraterone + Methylprednisolone, Androgen Deprivation Therapy + Apalutamide, Androgen Deprivation Therapy + Enzalutamide

Study Phase: Phase 2/Phase 3

Summary: This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinica...

View All Clinical Trials